Hope S. Rugo

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

4.9Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005

Top 4%

4.9DataRank

Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Papers

Driven by 51 papers — median percentile 96. Top paper: “Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer”.

Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2020.2535

N/A

6.3DataRank · unranked

225 citations

Angela DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans, Kathy S. Albain +74 more

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005

Top 4%

4.9DataRank

Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

Annals of Oncology(2020)10.1016/j.annonc.2020.05.012

N/A

3.1DataRank · unranked

106 citations

Sara A. Hurvitz, Jack A. Di Palma, Ron Bose, A. Jo Chien, Nicholas Iannotti +48 more

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer

Nature Communications(2022)10.1038/s41467-022-31238-y

N/A

1.9DataRank · unranked

78 citations

Filomena Housley, Christina Yau, Rachel Nakagawa, Juliane Winkler, Johanna M. Anttila +18 more

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03267-1

N/A

1.4DataRank · unranked

43 citations

Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian +55 more

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

The Lancet Oncology(2021)10.1016/s1470-2045(21)00589-1

N/A

0.917DataRank · unranked

451 citations

Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze +94 more

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00493-z

N/A

0.900DataRank · unranked

27 citations

Andres Forero‐Torres, Douglas Yee, Christina Yau, Denise M. Wolf, John Park +44 more

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Annals of Oncology(2020)10.1016/j.annonc.2020.08.2098

N/A

0.899DataRank · unranked

401 citations

Sara A. Hurvitz, Lida A. Mina, Hope S. Rugo, Ki Hoon Lee, Anthony Gonçalvès +15 more

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Cancer Cell(2021)10.1016/j.ccell.2021.05.009

N/A

0.873DataRank · unranked

337 citations

Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace +40 more

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

Cancer Cell(2023)10.1016/j.ccell.2023.04.008

N/A

0.777DataRank · unranked

177 citations

Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W. Sayaman, Derrick Renner, Ekaterina Kalashnikova +26 more

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Nature Communications(2021)10.1038/s41467-021-26019-y

N/A

0.648DataRank · unranked

74 citations

Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, L. J. van ‘t Veer, Douglas Yee +46 more

Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03266-2

N/A

0.610DataRank · unranked

13 citations

Jane Meisel, Christina Yau, Hope S. Rugo, Rita Nanda, Marie Davidian +52 more

Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa113

N/A

0.587DataRank · unranked

49 citations

Laura H. Hendrix, Terry Hyslop, William T. Barry, Eric P. Winer, Clifford A. Hudis +27 more

Genomewide Meta‐Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent‐Induced Sensory Peripheral Neuropathy

Clinical Pharmacology & Therapeutics(2020)10.1002/cpt.1958

N/A

0.581DataRank · unranked

47 citations

Chenling Xiong, Carol Ho, Taisei Mushiroda, J Chen, Flora Mulkey +13 more

Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)

npj Breast Cancer(2025)10.1038/s41523-025-00748-5

N/A

0.564DataRank · unranked

42 citations

Reshma Mahtani, Samantha Fisch, Naomi Dempsey, Sarah Premji, Angelina Raimonde +17 more

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00337-2

N/A

0.510DataRank · unranked

29 citations

Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar +50 more

Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

Annals of Oncology(2024)10.1016/j.annonc.2024.10.018

N/A

0.494DataRank · unranked

26 citations

David S. Wolf, Christina Yau, Lamorna Brown Swigart, Gillian L. Hirst, Claudine Isaacs +15 more

Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1329

N/A

0.483DataRank · unranked

24 citations

Oleksandr Savenkov, Erik Asmus, Karla V. Ballman, Janet H. Scott, John W. Park +6 more

Single-cell analysis of breast cancer metastasis reveals epithelial-mesenchymal plasticity signatures associated with poor outcomes

Journal of Clinical Investigation(2024)10.1172/jci164227

N/A

0.470DataRank · unranked

22 citations

Weilun Tan, Catherine M.M. Diadhiou, Christopher S. McGinnis, Aamna Abbasi, Saad Hasnain +22 more

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2256

N/A

0.457DataRank · unranked

20 citations

Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien +44 more

A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1076

N/A

0.449DataRank · unranked

19 citations

Amelia S. Gliwa, Siti Rahmaputri, H Dittrich, Melanie Majure, Hope S. Rugo +10 more

Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.101312

N/A

0.442DataRank · unranked

18 citations

Julia Wulfkuhle, Denise M. Wolf, Lamorna Brown Swigart, Christina Yau, Nicholas O’Grady +22 more

Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Primary Results From AMEERA-5

Journal of Clinical Oncology(2024)10.1200/jco.23.02036

N/A

0.434DataRank · unranked

17 citations

Sara A. Hurvitz, Joyce O'Shaughnessy, Suzette Delaloge, Hiroji Iwata, Hope S. Rugo +11 more

Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701)

Seminars in Oncology(2023)10.1053/j.seminoncol.2023.01.001

N/A

0.432DataRank · unranked

7 citations

David M. Zahrieh, Jun He, Blake Waechter, Julianne L. Holleran, Lionel D. Lewis +9 more

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy

Frontiers in Oncology(2022)10.3389/fonc.2022.802579

N/A

0.425DataRank · unranked

16 citations

Özge Gümüşay, Razelle Kurzrock, L. J. van ‘t Veer, Hope S. Rugo, Mark Jesus M. Magbanua

Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502

npj Breast Cancer(2024)10.1038/s41523-024-00683-x

N/A

0.419DataRank · unranked

7 citations

Roberto Salgado, Oleksander Savenkov, Karla V. Ballman, Erica L. Mayer, Mark Jesus M. Magbanua +11 more

Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.504

N/A

0.416DataRank · unranked

15 citations

Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, A. Jo Chien, Christina Yau +7 more

Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2928

N/A

0.406DataRank · unranked

14 citations

Ziad Ahmed, Rosalyn W. Sayaman, Lamorna Brown Swigart, Gillian L. Hirst, Christina Yau +13 more

Dissecting the contributions of tumor heterogeneity on metastasis at single-cell resolution

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.08.04.502697

N/A

0.345DataRank · unranked

9 citations

Weilun Tan, Catherine M.M. Diadhiou, Christopher S. McGinnis, Aamna Abbasi, Saad Hasnain +20 more

Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07339-1

N/A

0.292DataRank · unranked

6 citations

Samantha Fisch, Elene Tsopurashvili, Sai Sahitha Somepalle, Mia Salans, Harish N. Vasudevan +7 more

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

Nature Communications(2025)10.1038/s41467-025-65432-5

N/A

0.292DataRank · unranked

6 citations

Nayelis A. Manon, Denise M. Wolf, Samuel Rivero-Hinojosa, Ziad Ahmed, Rosalyn W. Sayaman +20 more

Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07555-9

N/A

0.255DataRank · unranked

4 citations

Mike Campbell, Christina Yau, A. Jo Chien, Anne M. Wallace, Claudine Isaacs +18 more

Tumor cell-adipocyte gap junctions activate lipolysis and contribute to breast tumorigenesis

bioRxiv (Cold Spring Harbor Laboratory)(2018)10.1101/277939

N/A

0.241DataRank · unranked

4 citations

Roman Camarda, Serghei Malkov, Lisa J. Zimmerman, Suzanne Manning, Dvir Aran +30 more

Combinatorial Immunotherapies Overcome MYC-Driven Immune Evasion

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.05.07.442684

N/A

0.241DataRank · unranked

4 citations

Filomena Housley, Christina Yau, Daniel Van de Mark, Rachel Nakagawa, Golzar Hemmati +11 more

Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1010

N/A

0.203DataRank · unranked

2 citations

Roberto Salgado, Oleksandr Savenkov, Karla V. Ballman, Mark Jesus M. Magbanua, Sherene Loi +11 more

355P Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial

Annals of Oncology(2023)10.1016/j.annonc.2023.09.534

N/A

0.165DataRank · unranked

2 citations

Elizabeth Price, Sara J. Venters, Wěi Li, Denise M. Wolf, Jessica Gibbs +14 more

Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba520

N/A

0.165DataRank · unranked

2 citations

Kevin Kalinsky, Christina Yau, A. Jo Chien, Judy C. Boughey, Erica Stringer-Reasor +15 more

Genome-Wide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy

medRxiv(2020)10.1101/2020.04.23.20076208

N/A

0.165DataRank · unranked

2 citations

Chenling Xiong, Carol Ho, Taisei Mushiroda, J Chen, Flora Mulkey +13 more

Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.514

N/A

0.104DataRank · unranked

1 citations

Denise M. Wolf, Christina Yau, Emanuel F. Petricoin, Paula R. Pohlmann, Lajos Pusztai +10 more

Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.510

N/A

0.104DataRank · unranked

1 citations

Amy S. Clark, Christina Yau, Denise M. Wolf, L. J. van ‘t Veer, Emily Douglas +10 more

Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial

Annals of Surgical Oncology(2025)10.1245/s10434-025-17864-y

N/A

0.104DataRank · unranked

1 citations

Katrina Dimitroff, Judy C. Boughey, Laura J. Esserman, Christina Yau, Julia Tchou +34 more

Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial)

UNC Libraries(2020)10.17615/e33z-ag80

N/A

0DataRank · unranked

0 citations

Harold J. Burstein, Lisa A. Carey, Antonio C. Wolff, Sara M. Tolaney, P. Kelly Marcom +15 more

A multidisciplinary approach to optimizing care of patients treated with alpelisib

The Breast(2021)10.1016/j.breast.2021.12.016

N/A

0DataRank · unranked

26 citations

Mario E. Lacouture, Marcus D. Goncalves, Umesh Masharani, Matti Aapro, Joyce O’Shaughnessy +1 more

Longitudinal Trajectories of Memory Performance in Patients with Early-Stage Breast Cancer

Journal of Oncology(2022)10.1155/2022/5899728

N/A

0DataRank · unranked

2 citations

Cutter A. Lindbergh, Susan Landau, Amy DeLuca, Jamie L. Eberling, William J. Jagust +4 more

374P Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial

Annals of Oncology(2023)10.1016/j.annonc.2023.09.552

N/A

0DataRank · unranked

1 citations

Saumya Umashankar, Muneeb M. Musthafa, Thomas Jones, Kasey Blevins, Timothy D. Brown +15 more

High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease

npj Breast Cancer(2023)10.1038/s41523-023-00526-1

N/A

0DataRank · unranked

7 citations

Laura A. Huppert, Lev Malevanchik, Hope S. Rugo, Alexis J. Combes, Michael J. Campbell +3 more

MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities

Cell Reports(2020)10.1016/j.celrep.2020.02.041

N/A

0DataRank · unranked

81 citations

Daniel Van de Mark, Meelad Amouzgar, Joyce V. Lee, Moufida Taileb, Alexandra Corella +13 more

Clinical course of multiple sclerosis and patient experiences during breast cancer treatment

Multiple Sclerosis Journal(2023)10.1177/13524585231175975

N/A

0DataRank · unranked

8 citations

Jessica Singh, Shane Poole, Annika Anderson, Ruth Ann Marrie, Hope S. Rugo +2 more

Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study

Breast Cancer Research(2025)10.1186/s13058-025-02121-7

N/A

0DataRank · unranked

1 citations

Michelle Jayaraj, Mia Salans, Kelsey Kuwahara, Maggie H. Zhou, Samantha Fisch +12 more

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Annals of Oncology(2022)10.1016/j.annonc.2022.04.072

N/A

0DataRank · unranked

21 citations

Anna Mrukwa, Christina Yau, Denise M. Wolf, Y.-Y. Chen, Ronald Balassanian +26 more

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

UNC Libraries(2020)10.17615/yrss-qx89

N/A

0DataRank · unranked

0 citations

Charles M. Perou, Madlyn Ferraro, Mothaffar F. Rimawi, Wing‐Keung Chiu, Antonio C. Wolff +15 more

Hope S. Rugo

Indexed papers

Top data-sharing exemplar

Papers